Literature DB >> 19767094

Dose-dense chemotherapy in advanced ovarian cancer.

Michael A Bookman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19767094     DOI： 10.1016/S0140-6736(09)61305-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.

Authors:  Weiqun Mao; Haley L Peters; Margie N Sutton; Aaron F Orozco; Lan Pang; Hailing Yang; Zhen Lu; Robert C Bast
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

2.  Weekly paclitaxel in ovarian cancer-the latest success story.

Authors:  A Jain; B Dubashi; K S Reddy; P Jain
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

3.  Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.

Authors:  Sarah Crawford
Journal:  Front Pharmacol       Date:  2013-06-25       Impact factor: 5.810

4.  Clinical trials and progress with paclitaxel in ovarian cancer.

Authors:  Sanjeev Kumar; Haider Mahdi; Christopher Bryant; Jay P Shah; Gunjal Garg; Adnan Munkarah
Journal:  Int J Womens Health       Date:  2010-11-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.